Références Scientifiques Consultez la littérature scientifique qui soutient nos cibles moléculaires et notre approche létale synthétique. juillet 2022 Guiding ATR and PARP inhibitor combinationswith chemogenomic screens Zimmermann M, Bernier C, Et Al. Cell Reports avril 2022 CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition Gallo D, Young JTF, Fourtounis J, et al. Nature février 2022 RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors Roulston A, Zimmermann M, Papp R, et al. Molecular Cancer Therapeutics juin 2020 Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity Sokolova AO, Yu EY, Cheng HH Clinical Cancer Research mai 2020 Identifying functional loss of ATM gene in patients with advanced cancer Pilie PG, Gheeya JS, Kyewalabye K, et al. ASCO février 2020 Analyse pan-cancer de génomes entiers Consortium ICGC/TCGA pour l'analyse pancancer du génome entier Nature février 2020 Pan-cancer analysis of whole genomes ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium Nature janvier 2020 CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions Su D, Feng X, Colic M, et al. ScienceDirect novembre 2019 Synthetic lethality as an engine for cancer drug target discovery Huang A, Garraway LA, Ashworth A, Weber B Nature Reviews Drug Discover juin 2019 A CRISPR Way to Identify Cancer Targets Hahn WC New England Journal of Medicine 12345 Notre pipeline comprend plusieurs programmes de développement. Voir Notre Pipeline
